prostate%20cancer
PROSTATE CANCER

Prostate cancer is the cancer that occurs in the male's prostate.

It is the most common cancer in men >50 years of age.

Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.

Supportive Therapy

Pharmacological Therapy

  • Mitoxantrone may be used for patients with symptomatic metastatic castration-resistant prostate cancer (CRPC) who have contraindications to Cabazitaxel or Radium-223 therapy
  • Denosumab and bisphosphonates (Eg Alendronate, Pamidronate, Zoledronic acid) may be suggested in patients with metastatic CRPC with bone metastasis to help prevent bone fractures, metastases, and other skeletal complications

Radiation Therapy

  • Recommended dose:
    • Non-vertebral metastases: 800 cGy x 1 fraction
    • Widespread bone metastases: Sr-89 or Sm-153 with or without focal external beam radiation therapy (EBRT)

Referral

  • Refer patient and his family to facilities that can provide palliative care services that can assist both the patient and his family while dealing with prostate cancer
  • Referral to pain clinics or palliative care team may also help in the symptomatic management of prostate cancer patients
Editor's Recommendations
Most Read Articles
Stephen Padilla, 4 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
4 days ago
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Jairia Dela Cruz, 03 Aug 2020
In the first year following percutaneous coronary intervention for acute coronary syndrome, ticagrelor and prasugrel cuts the risk of gastrointestinal (GI) bleeding by more than 30 percent compared with clopidogrel, as shown in a large real-world study.